Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih‐Hsin Yang, Jonathan W. Riess, Ullas Batra et al.|Clinical Lung Cancer|2025Cited by 3